PEPG - NASDAQ

PepGen Inc.

PEPG·NASDAQ

$1.46

+3.0%

HealthcareBiotechnology

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$101.28M

EPS-2.1200

P/E Ratio-0.69

Earnings Date08/06/2026

173.91M

Assets

15%

3Y-20.0%

5Y+1534.0%

10Y+4048.0%

26.46M

Total Liabilities

-18%

3Y-30.0%

5Y+2949.0%

10Y+8017.0%

147.44M

Total Equity

24%

3Y-18.0%

5Y+1409.0%

10Y+3713.0%

PepGen Inc. Funding & Solvency Profile

PEPG · NASDAQ

Current Assets

Cash & Cash Equivalents60.51M

Net Receivables0.00

Inventory0.00

Other Current Assets2.51M

Total Current Assets151 M

Non-Current Assets

Property, Plant & Equipment21.02M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets1.92M

Total Non-Current Assets23 M

Total Assets

173.91M

Financial Health Analysis

Current Ratio

11.94x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.18x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

138 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

87% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

PepGen Inc. Balance Sheet

PEPG • NASDAQ

PepGen Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	60.5M	49.4M	80.8M	181.8M	132.9M	9.8M	3.5M
Short-Term Investments	87.9M	70.8M	29.6M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	148.5M	120.2M	110.4M	181.8M	132.9M	9.8M	3.5M
Net Receivables	0.0	0.0	0.0	58K	4.7M	407K	230K
Other Receivables	0.0	0.0	0.0	58K	4.7M	407K	230K
Prepaids	0.0	0.0	0.0	0.0	2.3M	134K	53K
Other Current Assets	2.5M	3.6M	2.3M	4.3M	0.0	0.0	0.0
Total Current Assets	151M	123.8M	112.7M	186.1M	140M	10.3M	3.8M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	21M	25.1M	28.4M	29.9M	636K	323K	419K
Long-Term Investments	0.0	0.0	0.0	0.0	1.5M	0.0	0.0
Other Non-Current Assets	1.9M	2M	2M	1.5M	1.5M	0.0	0.0
Total Non-Current Assets	22.9M	27.1M	30.4M	31.4M	3.7M	323K	419K
Total Assets	173.9M	150.9M	143.1M	217.4M	143.6M	10.6M	4.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	822K	1.8M	1M	3.9M	3.2M	721K	141K
Accounts Payable	822K	1.8M	1M	1.4M	3.2M	721K	141K
Other Payables	0.0	0.0	0.0	2.6M	0.0	0.0	0.0
Accrued Expenses	0.0	8.2M	11.2M	6.9M	5.9M	89K	185K
Short Term Debt	3.2M	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	3.1M	3M	5.6M	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	2.6M	0.0	0.0	0.0
Other Current Liabilities	8.6M	3.6M	2.4M	2.4M	1.2M	28K	0.0
Total Current Liabilities	12.6M	16.7M	17.5M	18.8M	10.3M	838K	326K
NON-CURRENT LIABILITIES
Long Term Debt	13.8M	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	226K	30K	0.0
Total Non-Current Liabilities	13.8M	15.6M	17.1M	19M	226K	30K	0.0
Capital Lease Obligations	0.0	18.7M	20.1M	24.5M	0.0	0.0	0.0
Total Liabilities	26.5M	32.3M	34.6M	37.8M	10.5M	868K	326K
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	165.2M	16.1M	0.0
Common Stock	7K	3K	2K	2K	0.0	0.0	0.0
Additional Paid-In Capital	508.5M	390.1M	289.9M	282.6M	1.7M	119K	6.3M
Retained Earnings	-361.1M	-271.5M	-181.5M	-102.9M	-33.8M	-6.5M	-2.4M
Accumulated Other Comprehensive Income/Loss	11K	23K	34K	-81K	17K	-8K	-8K
Total Stockholders' Equity	147.4M	118.6M	108.4M	179.6M	133.1M	9.8M	3.9M
Total Equity	147.4M	118.6M	108.4M	179.6M	133.1M	9.8M	3.9M
SUMMARY
Total Liabilities & Equity	173.9M	150.9M	143.1M	217.4M	143.6M	10.6M	4.2M
Total Investments	87.9M	70.8M	29.6M	0.0	1.5M	0.0	0.0
Total Debt	17M	18.7M	20.1M	24.5M	0.0	0.0	0.0
Net Debt	-43.5M	-30.8M	-60.7M	-157.2M	-132.9M	-9.8M	-3.5M
Shares Outstanding	32,800,087	32,800,087	32,800,087	32,800,087	32,800,087	32,800,087	32,800,087

SEC Filings

PEPG - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 21, 2026	May 21, 2026	2026	View Filing
S-3 S-3 N/A	May 18, 2026	May 18, 2026		View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 18, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 30, 2026	March 30, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 04, 2026	March 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 04, 2026	March 04, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 04, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 08, 2025	December 08, 2025	2025	View Filing

Showing 1 to 10 of 91 filings

Related Guides

Blog Categories

Continue your PEPG research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.